Specialties

InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Presented By

Prof. Laurie Sehn, University of British Columbia, Canada

Trial

Phase 3, inMIND

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:34

High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

Presented By

Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA; Dr Sameh Gaballa, Lee Moffitt Cancer Center, FL, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:31

Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL

Presented By

Dr Catherine Diefenbach, NYU Langone Health, NY, USA

Trial

Phase 1, BO42203

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:29

ATALANTA-1: Promising data for novel CAR T-cell therapy

Presented By

Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands

Trial

Phase 1/2, ATALANTA-1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:27

ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Presented By

Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA

Trial

Phase 2, ZUMA-5

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:25

Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?

Presented By

Dr Timothy Fenske, Medical College of Wisconsin, WI, USA

Trial

Phase 3, EA4151

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:23

Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML

Presented By

Prof. Mark Levis, Johns Hopkins University, MD, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:20

Revumenib combination therapy associated with high response rates in relapsed/refractory AML

Presented By

Dr Ghayas Issa, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2, SAVE

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:17

Venetoclax plus azacitidine in young patients with AML

Presented By

Dr Daniel Pollyea, University of Colorado, CO, USA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:14

Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies

Presented By

Dr Jennifer Marvin-Peek, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:12

CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations

Presented By

Dr Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust, UK

Trial

Phase 3, AML19

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:09

High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML

Presented By

Dr Ioannis Mantzaris, Montefiore Medical Center, NY, USA

Trial

Phase 1

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:07

Findings from phase 3 uproleselan study in AML not all negative

Presented By

Prof. Daniel DeAngelo, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:05

Menin inhibitors on the rise in KMT2Ar acute leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 10:03

New standard-of-care for paediatric B-cell ALL

Presented By

Dr Rachel Rau, University of Washington, WA, USA

Trial

Phase 3, AALL1731

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:57

KCRd offers overall survival benefit over CRd in newly diagnosed MM

Presented By

Dr Charlotte Pawlyn, Institute of Cancer Research, UK

Trial

Phase 3, Myeloma XI/XI+

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:53

AQUILA: Early intervention with daratumumab extends survival in smouldering MM

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, AQUILA

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:49

Emerging mezigdomide-based options for heavily pre-treated MM

Presented By

Prof. Luciano Costa, University of Alabama at Birmingham, AL, USA

Trial

Phase 1/2, CA057-003

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:47

IFM2017-03: Daratumumab therapy fruitful for frail patients with MM

Presented By

Prof. Salomon Manier, University of Lille, France

Trial

Phase 3, IFM2017-03

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:44

CEPHEUS: Further support for daratumumab regimens in untreated MM

Presented By

Prof. Sonja Zweegman, Amsterdam University Medical Centre, the Netherlands

Trial

Phase 3, CEPHEUS

Conference

ASH 2024

Type

Peer-reviewed article

29 January 2025 09:42

Meet the Trialist: Prof. Mats Jerkeman on the ALTAMIRA trial

Expert

Prof. Mats Jerkeman, Skane University Hospital and Lund University, Sweden

Trial

Phase 2, ALTAMIRA

Conference

ASH 2024

23 December 2024 15:15

Meet the Expert: Prof C. Ola Landgren discusses the value of real-world evidence

Expert

Prof. C. Ola Landgren, Sylvester Comprehensive Cancer Center, University of Miami, FL, USA

Conference

ASH 2024

23 December 2024 15:07

Reclassification of AML Subtypes and Risk in Light of ICC and ELN2022

17 September 2024 13:51

The landscape of TP53 mutations and their prognostic impact in CLL

Presented By

Dr Consuelo Bertossi, University Hospital Ulm, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 15:11

Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?

Presented By

Dr Marc Hoffman, The University of Kansas Cancer Center, KS, USA

Trial

Phase 1, CC-220-DLBCL-001

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL

Presented By

Prof. Paolo Ghia, University Vita-Salute San Raffaele, Italy

Trial

Phase 3, SEQUOIA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes

Presented By

Dr Evgenii Shumilov, University of Münster, Germany

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

ECHO: Can we expect a novel standard of care in newly diagnosed MCL?

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, ECHO

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis

Presented By

Dr Abhishek Maiti, MD Anderson Cancer Center, TX, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL

Presented By

Prof. Jose Maria Ribera, Josep Carreras Leukaemia Research Institute, Spain

Trial

Phase 3, PhALLCON

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

APOLLO: ATRA plus ATO meets expectations in high-risk APL

Presented By

Prof. Uwe Platzbecker, Leipzig University Hospital, Germany

Trial

Phase 3, TUD-APOLLO-064

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

Excellent phase 3 results for asciminib in chronic myeloid leukaemia

Presented By

Prof. Andreas Hochhaus, Jena University Hospital, Germany

Trial

Phase 3, ASC4FIRST

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:25

AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:24

FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML

Presented By

Dr Wei-Ying Jen, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:20

CD40/CD47 inhibitor shows promise in high-risk MDS and AML

Presented By

Prof. Amer Zeidan, Yale University, CT, USA

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?

Presented By

Dr Anne Sophie Kubasch, University of Leipzig, Germany

Trial

Phase 2, RELAZA2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Can WGTS replace standard-of-care diagnostics in AML?

Presented By

Dr Anna Staffas, University of Gothenburg, Sweden

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial

Presented By

Prof. Thierry Facon, University of Lille, France

Trial

Phase 3, IMROZ

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM

Presented By

Prof. Pieter Sonneveld, Erasmus University Medical Center, the Netherlands

Trial

Phase 3, PERSEUS

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Post-intensification data confirm superiority of quadruple therapy in MM

Presented By

Prof. Marc Raab, University Hospital Heidelberg, Germany

Trial

Phase 3, GMMG-HD7

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

Promising phase 1 results for novel CAR T-cell therapy in MM

Presented By

Dr Binod Dhakal, Medical College of Wisconsin, WI, USA

Trial

Phase 1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:17

DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM

Presented By

Prof. Meletious Dimopoulos, University of Athens, Greece

Trial

Phase 3, DREAMM 8

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:16

Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients

Expert

Samantha Nier, Acute Leukemia Advocates Network

1 August 2024 14:16

Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials

Expert

Prof. C. Ola Landgren, University of Miami, FL, USA

Conference

EHA 2024

10 July 2024 16:53

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

Second-line therapy for multiple myeloma: Where we are now?

Presented By

Dr Francesca Gay, University of Torino, Italy

Conference

EMN 2024

23 April 2024 11:56

Treatment choices beyond immunotherapy in relapsed/refractory multiple myeloma

Presented By

Dr Rakesh Popat, University College London Hospitals, UK

Conference

EMN 2024

23 April 2024 11:42

The state of toxicities for immunotherapy for multiple myeloma

Presented By

Dr Alfred Garfall, University of Pennsylvania, PA, USA

Conference

EMN 2024

23 April 2024 11:39

Early multiple myeloma: where are immunotherapies headed?

Presented By

Dr Elias K. Mai, University Hospital Heidelberg, Germany

Conference

EMN 2024

23 April 2024 11:34

How does resistance arise for immunotherapy in relapsed/refractory multiple myeloma?

Presented By

Dr Nizar Bahlis, University of Calgary, Canada

Conference

EMN2024

23 April 2024 11:27

Functional imaging to complement bone marrow MRD in multiple myeloma

Presented By

Dr Elena Zamagni, Bologna University, Italy

Conference

EMN 2024

22 April 2024 13:04

Mass spectrometry detection of MRD for patients with multiple myeloma

Presented By

Dr Joannes F. M. Jacobs, Radboud University Medical Center, the Netherlands

Conference

EMN 2024

22 April 2024 13:02

Is MRD testing ready for prime time in multiple myeloma?

Presented By

Prof. Edward A. Stadtmauer, University of Pennsylvania, PA, USA

Conference

EMN 2024

22 April 2024 12:59

Managing transplant-ineligible elderly and frail patients with multiple myeloma

Presented By

Dr Salomon Manier, University of Lille, France

Conference

EMN 2024

22 April 2024 12:57

Treatment should be tailored to frailty status in patients with transplant-ineligible newly diagnosed multiple myeloma

Presented By

Dr Sara Bringhen, University of Torino, Italy

Conference

EMN 2024

22 April 2024 12:53

Interview: Advancing Myeloma Care

Expert

Prof. Monique Minnema, UMC Utrecht, the Netherlands

19 March 2024 14:42

Impact of Treatment on Multiple Myeloma Outcomes: Real-World Experience

19 March 2024 14:29

FLT3-ITD-specific MRD assessment useful for clinical management of AML

Presented By

Prof. Alexander Perl, University of Pennsylvania, PA, USA

Trial

Phase 3, QuANTUM-First

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:05

MRD status rather than FLT3-ITD co-mutation is linked to the benefit of CR1-allo in NPM1-mutated AML

Presented By

Dr Jad Othman, Royal North Shore Hospital, Australia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Promising results for quizartinib, venetoclax, and decitabine in FLT3-ITD mutated AML

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

AUGMENT-101: Excellent results for revumenib in R/R KMT2Ar leukaemia

Presented By

Dr Ibrahim Aldoss, City of Hope National Medical Center, CA, USA

Trial

Phase 2, AUGMENT-101

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:04

Blinatumomab reduces toxicity in the consolidation phase in paediatric high-risk B-cell ALL

Presented By

Prof. Martin Schrappe, Hong Kong College of Paediatricians, China

Trial

Phase 3, AIEOP-BFM ALL 2017

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Promising results for olverembatinib in combination with venetoclax for Ph+ ALL

Presented By

Dr Xiaoyuan Gong, Chinese Academy of Medical Sciences, China

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:02

Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants

Presented By

Dr Moritz Fürstenau, University of Cologne, Germany

Trial

Phase 2, CLL2-BAAG

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:01

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By

Dr Paolo Strati, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, SYMPATICO

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

KdD outperforms Kd in R/R MM also in participants with poor renal function

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, CANDOR

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:58

IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates

Presented By

Prof. Francesca Gay, University of Torino, Italy

Trial

Phase 3, IsKia

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:57

Novel standard-of-care in newly diagnosed MM

Presented By

Prof. Pieter Sonneveld, Erasmus MC, the Netherlands

Trial

Phase 3, Perseus

Conference

ASH 2023

Type

Peer-reviewed article

6 February 2024 16:34

Interview: Sandwich treatment model shows promise for mantle cell lymphoma

Expert

Dr Eliza Hawkes, Olivia Newton-John Cancer Wellness & Research Centre, Australia

Trial

Phase 2, WAMM

Conference

ASH 2023

4 January 2024 14:30

Meet the Trialist: Prof. Jeff Sharman on ELEVATE-TN

Expert

Prof. Jeff Sharman , The US Oncology Network and Willamette Valley Cancer Institute, Oregon, USA

Trial

Phase 3, ELEVATE-TN

Conference

ASH 2023

18 December 2023 18:14

How should multiple myeloma research change in a patient-oriented world?

19 September 2023 13:16

Overweight/obese BMI linked to worse survival in young people with leukemia

19 September 2023 13:11

How can we further improve lymphoma care?

Expert

Lorna Warwick, Lymphoma Coalition

14 September 2023 09:16

What every doctor should know about CLL in today’s treatment landscape

Expert

Dr Jennifer Brown, Dana-Farber Cancer Institute & Harvard University, MA, USA

21 August 2023 14:58

QuANTUM-First: Updated results on quizartinib in AML with FLT3-ITD

Presented By

Dr Richard Schlenk, University of Heidelberg, Germany

Trial

Phase 3, QuANTUM-First

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:54

MRD-positive patients with FLT3-ITD AML may benefit from post-transplant gilteritinib

Presented By

Dr Mark Levis, Johns Hopkins Hospital, Maryland, USA

Trial

MORPHO

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:45

Radiotherapy or not in patients with PMBCL after immunochemotherapy?

Presented By

Dr Maurizio Martelli, University Sapienza Roma, Italy

Trial

IELSG37

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:16

Zandelisib promising in relapsed/refractory indolent B-cell NHL

Presented By

Dr Takahiro Kumode, Kindai University, Japan

Trial

Phase 2, MIRAGE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:05

Promising data for epcoritamab plus R-CHOP in untreated DLBCL

Presented By

Dr Michael Clausen, Lillebaelt Hospital, Denmark

Trial

Phase 1/2, EPCORETM NHL-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:43

Can we combine teclistamab and nirogacestat for the treatment of RRMM?

Presented By

Dr Jeffrey Matous, Colorado Blood Cancer Institute, Colorado, USA

Trial

Phase 1, MajesTEC-2

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:21

Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM

Presented By

Prof. Sebastian Grosicki, Medical University of Silesia, Poland

Trial

Phase 1/2, DREAMM 5

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:15

CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM

Presented By

Dr Hermann Einsele, University of Würzburg, Germany

Trial

Phase 3, CARTITUDE-4

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 15:08

First-line nivolumab-AVD improves PFS both in adult and paediatric patients with advanced Hodgkin lymphoma

Presented By

Prof. Alex Herrera, City of Hope Medical Center, CA, USA

Trial

Phase 3, SWOG S1826

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:38

ASCO 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO 2023

26 June 2023 03:07

Long-term success for CD19 CAR T-cell therapy in CLL

Presented By

Dr Emily Liang, University of Washington, WA, USA

Trial

Phase 2

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:31

Next-generation cell therapies for cancer: CAR-NK cells

Presented By

Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By

Dr Anna Sureda, Catalan Institute of Oncology, Spain

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:15

Ide-cel superior to standard therapies in triple-class exposed RRMM

Presented By

Dr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain

Trial

Phase 3, KarMMa-3

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 16:48

ASCT or CAR T cell as first-line therapy for MM?

Presented By

Prof. Salomon Manier, Lille University Hospital, France

Trial

Phase 3, CARTITUDE-6

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:23

DETERMINATION: Does one size fit all in multiple myeloma?

Presented By

Dr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DETERMINATION

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:14

Quizartinib plus chemotherapy improves OS in patients with AML undergoing ASCT

Presented By

Prof. Radovan Vrhovac, University Hospital Centre Zagreb, Croatia

Trial

Phase 3, QuANTUM-First

Conference

EMBT 2023

Type

Peer-reviewed article

14 June 2023 20:07

Blinatumomab may improve outcomes in patients with B-cell ALL undergoing ASCT

Presented By

Dr Ayman Sayyed, University of Toronto, Canada

Conference

EBMT 2023

Type

Peer-reviewed article

14 June 2023 20:02